spec sheet10 rows
Neotrofin is the brand name for leteprinim potassium (development code AIT-082), a small purine derivative of hypoxanthine that was investigated as a neurotrophic and memory-enhancing agent. Developed by the company NeoTherapeutics, it works indirectly by prompting the brain to make more of its own neurotrophic factors, such as nerve growth factor. It was tested in Alzheimer's disease but the program was discontinued after only modest results, and it never reached approval.
- Stimulates the brain's own production of NGF and neurotrophin-3
- Orally active and crosses into the brain, unlike NGF itself
- Promotes neurite outgrowth and neuronal survival in preclinical models
- Neuroprotective through ERK signalling, with no hyperalgesia
- Was well tolerated in human Alzheimer's trials
Overview
Neotrofin, chemically leteprinim, is a hypoxanthine-based purine compound rather than a peptide or a classic receptor-targeting small molecule [1]. Instead of acting directly on neurons, it was described as an inducer of endogenous neurotrophic factors, raising the messenger RNA and protein levels of molecules such as nerve growth factor in the central nervous system [1]. It crosses into the brain, is absorbed well when taken by mouth, and has a half-life suitable for dosing once or twice daily [2]. It was developed by NeoTherapeutics as a candidate for age-related memory loss and neurodegeneration.
Preclinical studies suggested memory-enhancing and neuroprotective properties. In animal models, Neotrofin stimulated the outgrowth of neural processes and modestly promoted cholinergic sprouting after brain lesions, effects linked to its induction of nerve growth factor [1]. In humans, small early-phase trials found it to be safe and well tolerated, both in healthy older volunteers and in patients with mild Alzheimer's disease, with preliminary hints of benefit on some cognitive tests [2][4]. A separate study using brain imaging reported that Neotrofin altered glucose metabolism in regions related to memory and attention and was associated with improvements in memory and executive function in Alzheimer's patients [3]. These signals, however, were limited and inconsistent.
Neotrofin advanced into clinical development but ultimately did not succeed; the Alzheimer's program was discontinued after larger testing failed to show a convincing effect, and the compound was never approved for any indication [2]. Much of the supporting evidence is preclinical or comes from older, small trials, so it is best regarded as an experimental agent rather than a proven therapy. It is not a marketed medicine.
Mechanism
Neotrofin's proposed mechanism is indirect; rather than binding a specific receptor, it stimulates cells in the central nervous system to increase production of endogenous neurotrophic factors, most notably nerve growth factor, along with related molecules [1]. These neurotrophins in turn support neuronal survival, the growth of neurites, and the maintenance of cholinergic pathways important for memory, which is how the compound was thought to enhance cognition [1]. Consistent with this, animal studies showed increased neurotrophic-factor messenger RNA and enhanced cholinergic sprouting after injury following treatment [1]. In Alzheimer's patients, changes in regional brain glucose metabolism accompanied its cognitive effects, suggesting activity in circuits underlying memory and attention [3].
receptor fingerprint
(nerve growth factor)enhances synthesis + release
NT-3 (neurotrophin-3)upregulates
TrkA receptordownstream activation
ERK / MAPK pathwayactivates
Safetyrisks and cautions, not medical advice
Neotrofin was generally well tolerated in the human trials that were run, including Alzheimer's studies, with no signal of hyperalgesia. The catch is that the human efficacy data is thin and dated, the development program was discontinued after only modest results, and most of what we know is preclinical. Treat it as an experimental neurotrophic compound rather than a proven therapy.
Subjective profileweighing the evidence above
Well tolerated, well reasoned, and it still did not work; the Alzheimer's program was discontinued after modest results and nothing has replaced that evidence since. An interesting way to raise the brain's own neurotrophins, with no human efficacy to buy into.
Resources
This entry is here for reference.
Research
- 1.The effects of Neotrofin on septodentate sprouting after unilateral entorhinal cortex lesions in rats
- 2.A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients
- 3.Brain metabolic effects of Neotrofin in patients with Alzheimer's disease
- 4.A phase I study of AIT-082 in healthy elderly volunteers
4 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is Neotrofin?
A small-molecule purine (also known as AIT-082 or leteprinim) that nudges the brain to make more of its own nerve growth factor and related neurotrophins.
How does Neotrofin work?
Rather than being a growth factor itself, it enhances the synthesis and release of NGF and NT-3, which feed TrkA and ERK signalling for neurite outgrowth and neuroprotection.
Is Neotrofin proven in humans?
Not really. It reached Alzheimer's trials and was well tolerated, but the results were modest and the program was shelved, so treat it as an interesting neurotrophic tool with thin human data.
Why is it interesting?
It is one of the few orally active small molecules that raises endogenous neurotrophins and reaches the brain, which is the appeal versus injecting NGF directly.
Limitations of the evidence
- Human efficacy data is thin; the Alzheimer's program was discontinued after modest results
Notes and cautions
- Most evidence is preclinical or from older studies
- Not a proven therapy; best treated as experimental
- Not a marketed medicine